Nanoliposomal irinotecan for treating pancreatic cancer

References

• Malvezzi M, Bertuccio P, Rosso T, et al. European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women?. Ann Oncol. 2015;26:779–786.
   PubMed Web of Science ®Google Scholar
• Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605–1617.
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone AM, Krapcho M, et al. editors. SEER cancer statistics review, 1975-2012. Bethesda, MD: National Cancer Institute; 2015. Available from: http://seer.cancer.gov/csr/1975_2012/ based on November 2014 SEER data submission, posted to the SEER web site, April 2015.
   Google Scholar
• Neuzillet C, Tijeras-Raballand A, Bourget P, et al. State of the art and future directions of pancreatic ductal adenocarcinoma therapy. Pharmacol Ther. 2015;155:80–104.
   PubMed Web of Science ®Google Scholar
• Oettle H. Progress in the knowledge and treatment of advanced pancreatic cancer: from benchside to bedside. Cancer Treat Rev. 2014;40:1039–1047.
   PubMed Web of Science ®Google Scholar
• Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol. 2010;7:163–172.
   PubMed Web of Science ®Google Scholar
• Teague A, Lim K-H, Wang-Gillam A. Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies. Ther Adv Med Oncol. 2015;7:68–84.
   PubMed Web of Science ®Google Scholar
• Laurent S, Monsaert E, Boterberg T, et al. Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I-II study. Ann Oncol. 2009;20:1369–1374.
   PubMed Web of Science ®Google Scholar
• Kundranda M, Kachaamy T. Promising new therapies in advanced pancreatic adenocarcinomas. Future Oncol. 2014;10:2629–2641.
   PubMed Web of Science ®Google Scholar
• Sclafani F, Iyer R, Cunningham D, et al. Management of metastatic pancreatic cancer: current treatment options and potential new therapeutic targets. Crit Rev Oncol Hematol. 2015;95:318–336.
   PubMed Web of Science ®Google Scholar
• Grapsa D, Saif MW, Syrigos K. Targeted therapies for pancreatic adenocarcinoma: where do we stand, how far can we go? World J Gastrointest Oncol. 2015;7:172–177.
   PubMed Web of Science ®Google Scholar
• Van Loon K, Espinoza AM, Fogelman DR, et al. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas. 2014;43:343–349.
   PubMed Web of Science ®Google Scholar
• Marks E, Saif MW, Jia Y. Updates on first-line therapy for metastatic pancreatic adenocarcinoma. Jop. 2014;15:99–102.
   PubMedGoogle Scholar
• Pelzer U, Schwaner I, Stieler J, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011;47:1676–1681.
   PubMed Web of Science ®Google Scholar
• Oettle H, Riess H, Stieler JM, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014;32:2423–2429.
   PubMed Web of Science ®Google Scholar
• Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomized, open-label, phase 3 trial. Lancet. 2015. doi:10.1016/S0140-6736(15)00986-1. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Wall ME, Wani MC, Cook CE, et al. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminata. J Am Chem Soc. 1966;88:3888–3890.
   Web of Science ®Google Scholar
• Pommier Y. DNA topoisomerase I inhibitors: chemistry, biology and interfacial inhibition. Chem Rev. 2009;109:2894–2902.
   PubMed Web of Science ®Google Scholar
• Strumberg D, Pilon A, Smith M, et al. Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5ʹ-phosphorylated DNA double-strand breaks by replication runoff. Mol Cell Biol. 2000;20:3977–3987.
   PubMed Web of Science ®Google Scholar
• Stivers JT, Harris TK, Mildvan AS. Vaccinia DNA topoisomerase I: evidence supporting a free rotation mechanism for DNA supercoil relaxation. Biochemistry. 1997;36:5212–5222.
   PubMed Web of Science ®Google Scholar
• Stewart L, Redinbo MR, Qiu X, et al. A model for the mechanism of human topoisomerase I. Science. 1998;279:1534–1541.
   PubMed Web of Science ®Google Scholar
• Pommier Y. Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints. Curr Med Chem Anticancer Agents. 2004;4:429–434.
   PubMedGoogle Scholar
• Hsiang YH, Hertzberg R, Hecht S, et al. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem. 1985;260:14873–14878.
   PubMed Web of Science ®Google Scholar
• Liu YQ, Li WQ, Morris-Natschke SL, et al. Perspectives on biologically active camptothecin derivatives. Med Res Rev. 2015;35:753–789.
   PubMed Web of Science ®Google Scholar
• Schaeppi U, Fleischman RW, Cooney DA. Toxicity of camptothecin (NSC-100880). Cancer Chemother Rep 3. 1974;5:25–36.
   PubMedGoogle Scholar
• Muggia FM, Creaven PJ, Hansen HH, et al. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep. 1972;56:515–521.
   PubMedGoogle Scholar
• Gottlieb JA, Guarino AM, Call JB, et al. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep. 1970;54:461–470.
   PubMedGoogle Scholar
• Chazin Ede L, Reis Rda R, Junior WT, et al. An overview on the development of new potentially active camptothecin analogs against cancer. Mini Rev Med Chem. 2014;14:953–962.
   PubMed Web of Science ®Google Scholar
• Brave M, Dagher R, Farrell A, et al. Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer. Oncology (Williston Park). 2006;20:1401–1404.
   PubMed Web of Science ®Google Scholar
• Venook A. Critical evaluation of current treatments in metastatic colorectal cancer. Oncologist. 2005;10:250–261.
   PubMed Web of Science ®Google Scholar
• Kalra AV, Kim J, Klinz SG, et al. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion. Cancer Res. 2014;74:7003–7013.
   PubMed Web of Science ®Google Scholar
• Teicher BA. Next generation topoisomerase I inhibitors: rationale and biomarker strategies. Biochem Pharmacol. 2008;75:1262–1271.
   PubMed Web of Science ®Google Scholar
• Kuppens IE, Beijnen J, Schellens JH. Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration. Clin Colorectal Cancer. 2004;4:163–180.
   PubMedGoogle Scholar
• Bala V, Rao S, Boyd BJ, et al. Prodrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38. J Control Release. 2013;172:48–61.
   PubMed Web of Science ®Google Scholar
• Kieler-Ferguson HM, Frechet JM, Szoka FC Jr. Clinical developments of chemotherapeutic nanomedicines: polymers and liposomes for delivery of camptothecins and platinum (II) drugs. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013;5:130–138.
   PubMed Web of Science ®Google Scholar
• Tredan O, Galmarini CM, Patel K, et al. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007;99:1441–1454.
   PubMed Web of Science ®Google Scholar
• Neesse A, Michl P, Frese KK, et al. Stromal biology and therapy in pancreatic cancer. Gut. 2011;60:861–868.
   PubMed Web of Science ®Google Scholar
• Keen J. A step towards a new targeted nanotherapy for pancreatic cancer. Cancer Biol Ther. 2008;7:1591–1592.
   PubMed Web of Science ®Google Scholar
• Wagener DJ, Verdonk HE, Dirix LY, et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol. 1995;6:129–132.
   PubMed Web of Science ®Google Scholar
• Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004;22:3776–3783.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–1825.
   PubMed Web of Science ®Google Scholar
• Marsch Rde W, Talamonti MS, Katz MH, et al. Pancreatic cancer and FOLFIRINOX: a new era and new questions. Cancer Med. 2015;4:853–863.
   PubMed Web of Science ®Google Scholar
• Al Haddad AH, Adrian TE. Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma. Expert Opin Investig Drugs. 2014;23:1499–1515.
   PubMed Web of Science ®Google Scholar
• Noble CO, Krauze MT, Drummond DC, et al. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res. 2006;66:2801–2806.
   PubMed Web of Science ®Google Scholar
• Drummond DC, Noble CO, Guo Z, et al. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res. 2006;66:3271–3277.
   PubMed Web of Science ®Google Scholar
• Chang TC, Shiah HS, Yang CH, et al. Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients. Cancer Chemother Pharmacol. 2015;75:579–586.
   PubMed Web of Science ®Google Scholar
• Haran G, Cohen R, Bar LK, et al. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta. 1993;11521:201–215.
   Web of Science ®Google Scholar
• Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994;54:987–992.
   PubMed Web of Science ®Google Scholar
• Chen P-Y, Ozawa T, Drummond DC, et al. Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts. Neuro Oncol. 2013;15:189–197.
   PubMed Web of Science ®Google Scholar
• Noble CO, Krauze MT, Drummond DC, et al. Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors. Nanomedicine (Lond). 2014;9:2099–2108.
   PubMed Web of Science ®Google Scholar
• Kang MH, Wang J, Makena MR, et al. Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing’s family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression. Clin Cancer Res. 2015;21:1139–1150.
   PubMed Web of Science ®Google Scholar
• Zheng J, Klinz SG, De Souza R, et al. Longitudinal tumor hypoxia imaging with [(18)F]FAZA-PET provides early prediction of nanoliposomal irinotecan (nal-IRI) treatment activity. EJNMMI Res. 2015;5:57.
   PubMed Web of Science ®Google Scholar
• Roy AC, Park SR, Cunningham D, et al. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma. Ann Oncol. 2013;24:1567–1573.
   PubMed Web of Science ®Google Scholar
• Ko AH, Tempero MA, Shan YS, et al. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer. 2013;109:920–925.
   PubMed Web of Science ®Google Scholar
• Chen LT, Von Hoff D, Li CP, et al. Expanded analyses of Napoli-1: Phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy. J Clin Oncol. 2015;33(suppl 4):abstr 234.
   Google Scholar